Ripple Therapeutics Research on Polymer-Free Drug Delivery Published in Nature Communications

Ontario Industry Updates
Written By Doriane Rey
Ripple.png

Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, announced that the article Polymer-Free Corticosteroid Dimer Implants for Controlled and Sustained Drug Delivery was recently published in Nature Communications. The article describes Ripple's Epidel™ technology platform which is founded on a discovery that drugs can be engineered into drug delivery implants without the use of polymers or excipients.

Doriane Rey
Previous

Toronto biotech startup Adela raises $60-million from top U.S. investors
Next

New method can improve drug delivery in implants